Can a targeted pill stop breast Cancer's return? new trial hopes so.
NCT ID NCT07190443
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 30 times
Summary
This study tests whether adding the drug abemaciclib to standard hormone therapy can help prevent breast cancer from coming back in people whose cancer has already returned in the same area (chest, breast, or nearby lymph nodes). About 290 participants will receive either hormone therapy alone or hormone therapy plus abemaciclib for two years. The goal is to see if the combination delays or stops further cancer spread, but it is not a cure—ongoing monitoring and treatment may still be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute Hospital of JFCR
RECRUITINGKoto-ku, Tokyo, 135-8550, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.